Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.

Article  PubMed  Google Scholar 

Chargari C, Peignaux K, Escande A, Renard S, Lafond C, Petit A. Lam Cham Kee D, Durdux C, Haie-Meder C: Radiotherapy of cervical cancer. Cancer Radiother. 2022;26(1-2):298–308.

Article  CAS  PubMed  Google Scholar 

Mayadev JS, Ke G, Mahantshetty U, Pereira MD, Tarnawski R, Toita T. Global challenges of radiotherapy for the treatment of locally advanced cervical cancer. Int J Gynecol Cancer. 2022;32(3):436–45.

Article  PubMed  PubMed Central  Google Scholar 

Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393(10167):169–82.

Article  PubMed  Google Scholar 

Schaue D, McBride WH. Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol. 2015;12(9):527–40.

Article  PubMed  PubMed Central  Google Scholar 

Jarosz-Biej M, Smolarczyk R, Cichon T, Kulach N. Tumor microenvironment as a “Game Changer” in cancer radiotherapy. Int J Mol Sci. 2019;20(13)

Citrin DE. Recent developments in radiotherapy. N Engl J Med. 2017;377(11):1065–75.

Article  CAS  PubMed  Google Scholar 

Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2020;40(5):602–8.

Article  CAS  PubMed  Google Scholar 

Sherer MV, Kotha NV, Williamson C, Mayadev J. Advances in immunotherapy for cervical cancer: recent developments and future directions. Int J Gynecol Cancer. 2022;32(3):281–7.

Article  PubMed  Google Scholar 

Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol. 2011;29(36):4828–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Twomey JD, Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J. 2021;23(2):39.

Article  PubMed  Google Scholar 

Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, Tewari KS, Salman P, Hoyos Usta E, Yanez E, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021;385(20):1856–67.

Article  CAS  PubMed  Google Scholar 

Arina A, Gutiontov SI, Weichselbaum RR. Radiotherapy and immunotherapy for cancer: from “Systemic” to “Multisite”. Clin Cancer Res. 2020;26(12):2777–82.

Article  CAS  PubMed  Google Scholar 

Yu WD, Sun G, Li J, Xu J, Wang X. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy. Cancer Lett. 2019;452:66–70.

Article  CAS  PubMed  Google Scholar 

Zhang Z, Liu X, Chen D, Yu J. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther. 2022;7(1):258.

Article  PubMed  PubMed Central  Google Scholar 

Demaria S, Coleman CN, Formenti SC. Radiotherapy: changing the game in immunotherapy. Trends Cancer. 2016;2(6):286–94.

Article  PubMed  PubMed Central  Google Scholar 

Weichselbaum RR, Liang H, Deng L, Fu YX. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol. 2017;14(6):365–79.

Article  CAS  PubMed  Google Scholar 

Pointer KB, Pitroda SP, Weichselbaum RR. Radiotherapy and immunotherapy: open questions and future strategies. Trends Cancer. 2022;8(1):9–20.

Article  CAS  PubMed  Google Scholar 

Liu Y, Dong Y, Kong L, Shi F, Zhu H, Yu J. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol. 2018;11(1):104.

Article  PubMed  PubMed Central  Google Scholar 

Donlon NE, Power R, Hayes C, Reynolds JV, Lysaght J. Radiotherapy, immunotherapy, and the tumour microenvironment: turning an immunosuppressive milieu into a therapeutic opportunity. Cancer Lett. 2021;502:84–96.

Article  CAS  PubMed  Google Scholar 

Wang Y, Deng W, Li N, Neri S, Sharma A, Jiang W, Lin SH. Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future directions. Front Pharmacol. 2018;9:185.

Article  PubMed  PubMed Central  Google Scholar 

Walle T, Martinez Monge R, Cerwenka A, Ajona D, Melero I, Lecanda F. Radiation effects on antitumor immune responses: current perspectives and challenges. Ther Adv Med Oncol. 2018;10:1758834017742575.

Article  PubMed  PubMed Central  Google Scholar 

Shen R, Liu D, Wang X, Guo Z, Sun H, Song Y, Wang D. DNA damage and activation of cGAS/STING pathway induce tumor microenvironment remodeling. Front Cell Dev Biol. 2021;9:828657.

Article  PubMed  Google Scholar 

Huang RX, Zhou PK. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther. 2020;5(1):60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shi F, Su J, Wang J, Liu Z, Wang T. Activation of STING inhibits cervical cancer tumor growth through enhancing the anti-tumor immune response. Mol Cell Biochem. 2021;476(2):1015–24.

Article  CAS  PubMed  Google Scholar 

Taylor BC, Balko JM. Mechanisms of MHC-I downregulation and role in immunotherapy response. Front Immunol. 2022;13:844866.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12(12):860–75.

Article  CAS  PubMed  Google Scholar 

Oltean T, Lippens L, Lemeire K, De Tender C, Vuylsteke M, Denys H, Vandecasteele K, Vandenabeele P, Adjemian S. Association of cell death markers with tumor immune cell infiltrates after chemo-radiation in cervical cancer. Front Oncol. 2022;12:892813.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang M, Olaoba OT, Zhang C, Kimchi ET, Staveley-O'Carroll KF, Li G: Cancer immunotherapy and delivery system: an update. Pharmaceutics. 2022;14(8):1630.

Liu J, Chen Z, Li Y, Zhao W, Wu J, Zhang Z. PD-1/PD-L1 checkpoint inhibitors in tumor immunotherapy. Front Pharmacol. 2021;12:731798.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Frenel JS, Le Tourneau C, O'Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, van Brummelen EMJ, Rugo HS, Thomas S, Saraf S, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol. 2017;35(36):4035–41.

Article  CAS  PubMed  Google Scholar 

Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, Manzuk L, Piha-Paul SA, Xu L, Zeigenfuss S, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2019;37(17):1470–8.

Article  CAS  PubMed  Google Scholar 

Xu Q, Wang J, Sun Y, Lin Y, Liu J, Zhuo Y, Huang Z, Huang S, Chen Y, Chen L, et al. Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase II trial. J Clin Oncol. 2022;40(16):1795–805.

Article  PubMed  PubMed Central  Google Scholar 

Nishio S, Yonemori K, Usami T, Minobe S, Yunokawa M, Iwata T, Okamoto A, Aoki Y, Itamochi H, Takekuma M, et al. Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: results from KEYNOTE-826. Cancer Sci. 2022;113(11):3877–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vicier C, Isambert N, Cropet C, Hamimed M, Osanno L, Legrand F, de La Motte RT, Ciccolini J, Goncalves A. MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors. ESMO Open. 2022;7(6):100646.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• O'Malley DM, Neffa M, Monk BJ, Melkadze T, Huang M, Kryzhanivska A, Bulat I, Meniawy TM, Bagameri A, Wang EW et al: Dual PD-1 and CTLA-4 checkpoint blockade using balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer: an open-label phase II study. J Clin Oncol. 2022, 40(7):762-771. An open-label phase II study suggested dual PD-1 and CTLA-4 checkpoint blockade combination as second-line treatment for advanced cervical cancer.

Ferrall L, Lin KY, Roden RBS, Hung CF, Wu TC. Cervical cancer immunotherapy: facts and hopes. Clin Cancer Res. 2021;27(18):4953–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Ahmed K, Quick A, Bixel K, Kim Y, Lemerond E, Chon H, Chern J, Fernandez D, Hoffman M, Kim S: Atezolizumab and stereotactic body radiation therapy in metastatic, recurrent or persistent cervical cancer: interim results from a non-randomized, open-label phase II multi-institutional study. Int J Radiat Oncol Biol Phys. 2022;114(3):S89-S90. The phase II multi-institutional trial showed that atezolizumab and SBRT was well tolerated in the first stage of the phase II trial.

Da Silva DM, Enserro DM, Mayadev JS, Skeate JG, Matsuo K, Pham HQ, Lankes HA, Moxley KM, Ghamande SA, Lin YG, et al. Immune activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation (GOG-9929). Clin Cancer Res. 2020;26(21):5621–30.